Anaveon Company

Anaveon are developing IL-2 complexes which selectively promote effector T cell functions. Our compounds act as effective immune adjuvants with a broad therapeutic window and marked preclinical efficacy against cancer either as monotherapy or in combination with other therapies.
Industry: PharmTech
Headquarters: Basel

Visit Website
Register and Claim Ownership